| Literature DB >> 29983770 |
Konstantinos Valsamidis1, Konstantinos Titelis1, Dimitrios Rachovitsas2, Iordanis Konstantinidis3, Konstantinos Markou3, Stefanos Triaridis2.
Abstract
Introduction Nasal septoplasty is considered the treatment of choice for nasal obstruction due to septal deviation. An ongoing discussion among rhinologists is whether it is reasonable to perform objective measurements of nasal patency pre or postoperatively routinely. Objective The primary aim of this study was to identify the short- and long-term functional benefits for patients undergoing septal surgery, as assessed by acoustic rhinometry (AR). The secondary goal was to evaluate the short- and long-term perception of symptom relief and disease-specific quality of life (QoL) outcomes on the part of the patients. Methods This was a prospective observational study in which AR was utilized for the assessment of nasal patency preoperatively and 1, 6 and 36 months after septoplasty. Total 40 patients who underwent septoplasty filled out the Nasal Obstruction Septoplasty Effectiveness (NOSE) questionnaire and the Glasgow Benefit Inventory (GBI) to assess their subjective improvement in nasal obstruction symptoms and the changes in their QoL. Results There were statistically significant improvements in nasal patency, mean postoperative NOSE and GBI scores postoperatively. However, there was no correlation between the mean NOSE and GBI scores and the AR measurements. Furthermore, the GBI scores tended to decrease as the postoperative period increased. Conclusion The present study confirms that septoplasty significantly increases nasal patency and causes a significant subjective improvement in nasal obstruction symptoms. The absence of a statistically significant correlation among the objective measurements, the symptom scores, and the patients' low GBI scores indicates that factors other than the anatomical findings may also contribute to the patients' perception of QoL.Entities:
Keywords: acoustic rhinometry; nasal obstruction; quality of life; septoplasty
Year: 2018 PMID: 29983770 PMCID: PMC6033599 DOI: 10.1055/s-0037-1613688
Source DB: PubMed Journal: Int Arch Otorhinolaryngol ISSN: 1809-4864
Pre and postoperative (at 1, 6, 36 months after surgery) minimal cross-sectional area (MCA1 and MCA2) measurement with acoustic rhinometry
| Variable | Preop mean (SD) | Postop1 mean (SD) |
| Preop mean (SD) | Postop6 |
| Preop mean (SD) | Postop36 |
|
|---|---|---|---|---|---|---|---|---|---|
| MCA1 (cm 2 ) | 0.49 ± 0.15 | 0.83 ± 0.60 | 0.000 | 0.49 ± 0.15 | 0.90 ± 0.08 | 0.000 | 0.49 ± 0.15 | 0.85 ± 0.13 | 0.000 |
| MCA2 (cm 2 ) | 0.47 ± 0.15 | 1.12 ± 0.49 | 0.000 | 0.47 ± 0.15 | 1.29 ± 0.47 | 0.000 | 0.47 ± 0.15 | 1.15 ± 0.47 | 0.000 |
Abbreviations: MCA1, minimal cross-sectional area at the first 2 cm of the nasal cavity; MCA2, minimal cross-sectional area between 2–5 cm into the nasal cavity; Preop, preoperatively; Postop1, 1 month postoperatively; Postop6, 6 months postoperatively; Postopo36, 36 months postoperatively; SD, standard deviation.
Note: a Wilcoxon signed-rank test for paired samples.
Pre and postoperative (at 1, 6, 36 months after surgery) NOSE scores
| Variable | Preop mean (SD) | Postop1 mean (SD) |
| Preop mean (SD) | Postop6 mean (SD) |
|
|---|---|---|---|---|---|---|
| NOSE | 79.12 ± 15.05 | 19.87 ± 15.08 | 0.000 | 79.12 ± 15.05 | 8.87 ± 8.35 | 0.000 |
|
|
|
|
|
|
| |
| NOSE | 79.12 ± 15.05 | 15.12 ± 8.95 | 0.000 | 8.87 ± 8.35 | 15.12 ± 8.95 | 0.000 |
Abbreviations: NOSE, Nasal Obstruction Septoplasty Effectiveness Questionnaire; Preop, preoperatively; Postop1, 1 month postoperatively; Postop6, 6 months postoperatively; Postop36, 36 months postoperatively; SD, standard deviation.
Note: a Wilcoxon signed-rank test for paired samples.
Postoperative (at 1, 6, 36 months after surgery) GBI scores - total and subscales
| Variable | Postop1 mean (SD) | Postop6 mean (SD) |
| Postop6 mean (SD) | Postop36 mean (SD) |
|
|---|---|---|---|---|---|---|
| GBI total | 22.36 ± 12.26 | 25.76 ± 13.13 | 0.000 b | 25.76 ± 13.13 | 19.86 ± 9.27 | 0.001 b |
| GBI general | 26.04 ± 15.61 | 30.31 ± 15.87 | 0.000 b | 30.31 ± 15.87 | 22.49 ± 12.86 | 0.000 b |
| GBI social | 4.16 ± 11.78 | 6.25 ± 12.33 | 0.009 | 6.25 ± 12.33 | 5.2 ± 11.43 | 0.219 |
| GBI physical | 26.24 ± 22.29 | 31.24 ± 22.70 | 0.02 | 31.24 ± 22.70 | 20.83 ± 22.24 | 0.003 |
Abbreviations: GBI, Glasgow Benefit Inventory; Preop, preoperatively; Postop1, 1 month postoperatively; Postop6, 6 months postoperatively; Postop36, 36 months postoperatively; SD, standard deviation.
Notes: a Wilcoxon signed-rank test for paired samples. b Paired samples t -test.
Correlation between MCA1 and MCA2 values and NOSE and GBI scores 36 months postoperatively
| NOSE postop36 | GBI postop36 | |
|---|---|---|
| MCA1 postop36 | ||
| r-value a | –0.085 | 0.114 |
|
| 0.604 | 0.482 |
|
| ||
| r-value a | -0.125 | 0.085 |
|
| 0.444 | 0.6 |
Abbreviations: GBI, Glasgow Benefit Inventory; MCA1, minimal cross-sectional area at the first 2 cm of the nasal cavity; MCA2, minimal cross-sectional area between 2–5 cm into the nasal cavity; NOSE, Nasal Obstruction Septoplasty Effectiveness Questionnaire.
Note: a Spearman's (rho) correlation coefficient.
Comparison of postoperative (36 months after surgery) total GBI scores between the groups above below criterion A (median MCA1 value), criterion B (median MCA2 value) and criterion C (median value of the NOSE score)
| Criterion A | Criterion B | Criterion C | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Above (
|
Below (
|
Above (
|
Below (
|
Above (
|
Below (
| ||||
| Variable | Mean (SD) | Mean (SD) |
| Mean (SD) | Mean (SD) |
| Mean (SD) | Mean (SD) |
|
| GBI postop36 | 20.64 (10.03) | 20.33 (8.54) | 0.934 | 21.78 (9.28) | 19.45 (9.44) | 0.528 | 23.56 (9.16) | 18.24 (9.23) | 0.151 |
Abbreviations: GBI, Glasgow Benefit Inventory; MCA1, minimal cross-sectional area at the first 2 cm of the nasal cavity; MCA2, minimal cross-sectional area between 2–5 cm into the nasal cavity; NOSE, Nasal Obstruction Septoplasty Effectiveness Questionnaire; postop36, 36 months postoperatively; SD, standard deviation.
Note: a Mann-Whitney U test.
Comparison of postoperative (at 6 and 36 months after surgery) minimal cross-sectional area (MCA1 and MCA2) measurement with acoustic rhinometry among the groups with different degrees of septum deviation
| Variable | MCA1 postop6 mean (SD) |
| MCA2 postop6 mean (SD) |
| MCA1 postop36 |
| MCA2 postop36 mean (SD) |
|
|---|---|---|---|---|---|---|---|---|
|
Grade I (
| 0.86 ± 0.05 | 0.000 | 1.36 ± 0.59 | 0.000 | 0.93 ± 0.15 | 0.03 | 1.31 ± 0.52 | 0.04 |
|
Grade II (
| 0.77 ± 0.35 | 0.9 ± 0.09 | 0.82 ± 0.11 | 1.10 ± 0.41 | ||||
|
Grade III (
| 0.69 ± 0.08 | 0.69 ± 0.1 | 0.76 ± 0.17 | 0.86 ± 0.12 |
Abbreviations: MCA1, minimal cross-sectional area at the first 2 cm of the nasal cavity; MCA2, minimal cross sectional area between 2–5 cm into the nasal cavity; postop6, 6 months postoperatively; postopo36, 36 months postoperatively; SD, standard deviation.
Note: a Kruskal-Wallis test.
Comparison of postoperative (at 6 and 36 months after surgery) NOSE and GBI scores among the groups with different degrees of septum deviation
| Variable | NOSE postop6 mean (SD) |
| GBI postop6 mean (SD) |
| NOSE Postop36 |
| GBI postop36 mean (SD) |
|
|---|---|---|---|---|---|---|---|---|
|
Grade I (
| 12.63 ± 11.34 | 0.000 | 32.74 ± 8.61 | 0.001 | 10.26 ± 3.52 | 0.001 | 22.95 ± 8.72 | 0.119 |
|
Grade II (
| 20.26 ± 7.58 | 15.59 ± 4.47 | 16.92 ± 9.9 | 18.37 ± 9.03 | ||||
|
Grade III (
| 45 ± 5.34 | 8.68 ± 4.55 | 23.12 ± 10.32 | 14.93 ± 9.26 |
Abbreviations: GBI, Glasgow Benefit Inventory; NOSE, Nasal Obstruction Septoplasty Effectiveness Questionnaire; postop6, 6 months postoperatively, postopo36, 36 months postoperatively; SD, standard deviation.
Note: a Kruskal-Wallis test.